Evidence map›Paper›PMID 36595540›Full record

ArticleClinical cancer research : an official journal of the American Association for Cancer Research2023

Response to Neoadjuvant Targeted Therapy in Operable Head and Neck Cancer Confers Survival Benefit.

Marco A Mascarella, Tolani F Olonisakin, Purva Rumde, Varun Vendra, Melonie A Nance, Seungwon Kim, Mark W Kubik, Shaum S Sridharan, Robert L Ferris, Moon J Fenton and 8 more

3 registry-linked trialsOpen access · bronzeAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
3.4field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00779389 phase1completednot on this map

Comparison of Biomarker Modulation by Inhibition of EGFR and/or Src Family Kinases Using Erlotinib and Dasatinib in Head and Neck Lung Cancers

TypeinterventionalSponsorUniversity of PittsburghRan2009 to 2014Enrolled58ConditionsHead and Neck Cancer, Non Small Cell Lung CancerArmsErlotinib, Dasatinib + Placebo, Erlotinib plus Dasatinib, Placebo
NCT01218048 phase2completednot on this map

Phase II Study of Neoadjuvant Immune Biomarker Modulation With Cetuximab Followed by Adjuvant Therapy With Concurrent Chemoradiotherapy or Radiotherapy With or Without Cetuximab for Locally Advanced Head and Neck Squamous Cell Carcinoma

TypeinterventionalSponsorRobert FerrisRan2011 to 2017Enrolled40ConditionsSquamous Cell Carcinoma of the Head and NeckArmsCetuximab, Surgery, Post-surgical radiation, Cisplatin or carboplatin
NCT02473731 phase1completednot on this map

A Window of Opportunity Study of KTN3379 in Surgically Resectable Head and Neck Cancer Patients

TypeinterventionalSponsorCelldex TherapeuticsRan2015 to 2016Enrolled12ConditionsSquamous Cell Carcinoma of the Head and NeckArmsKTN3379
3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Neoadjuvant Capecitabine in Operable HPV-Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2024
    Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 6 institutions in 2 countries.

Marco A Mascarella *Division of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-8880-805X
Tolani F Olonisakin *Division of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-8342-3409
Purva RumdeDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0003-0041-9074
Varun VendraDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-8908-9843
Melonie A NanceDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-2822-8096
Seungwon KimDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0003-1379-2601
Mark W KubikDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-8646-9920
Shaum S SridharanDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0001-6049-1508
Robert L FerrisDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0001-6605-2071
Moon J FentonUPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-6483-0009
Daniel R ClayburghDepartment of Otolaryngology-Head and Neck Surgery, Oregon Health & Science University, Portland, Oregon.ORCID 0000-0002-3296-4926
James P OhrUPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-7037-6404
Sonali C JoyceUPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0003-4839-825X
Malabika SenUPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-3931-140X
James G HermanUPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0001-8102-1740
Jennifer R GrandisDepartment of Otolaryngology-Head and Neck Surgery, University of California, San Francisco, California.ORCID 0000-0002-1013-8965
Dan P ZandbergUPMC Hillman Cancer Center, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0002-1002-8301
Umamaheswar DuvvuriDivision of Head and Neck Surgery, Department of Otolaryngology-Head and Neck Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.ORCID 0000-0003-1968-3756
UPMC Hillman Cancer Center · USUniversity of Pittsburgh Medical Center · USJewish General Hospital · CAOregon Health & Science University · USUniversity of California, San Francisco · USUPMC Health System · US

Funding

VECTOR CORE FACILITYP30CA047904 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI Jessie Nedrow · 1988 to 2026
$158.0M
WILD TYPE P53-BASED ADJUVANT IMMUNOTHERAPY FOR SCCHNP50CA097190 · NCI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI CHRISTOPHER J. BAKKENIST · 2004 to 2026
$49.6M
Integrating genomics and the protein interactome for HPV+ head and neck cancer therapyR35CA231998 · NCI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GRANDIS, JENNIFER RUBIN · 2018 to 2024
$6.2M
Inhibition of lysosomal flux in carcinogen-induced head and neck cancerR01DE028343 · NIDCR · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DUVVURI, UMAMAHESWAR · 2019 to 2023
$1.9M
BLRD VA I01 BX005340National Institute of Dental and Craniofacial Research (NIDCR) DE028343NCI NIH HHS P30 CA047904NCI NIH HHS P50 CA097190NCI NIH HHS R35 CA231998NIDCR NIH HHS R01 DE028343U.S. Department of Veterans Affairs (VA) I01-BX5340
6 · The paper itself

Abstract

purposeNeoadjuvant targeted therapy provides a brief, preoperative window of opportunity that can be exploited to individualize cancer care based on treatment response. We investigated whether response to neoadjuvant therapy during the preoperative window confers survival benefit in patients with operable head and neck squamous cell carcinoma (HNSCC). PATIENTS AND

methodsA pooled analysis of treatment-naïve patients with operable HNSCC enrolled in one of three clinical trials from 2009 to 2020 (NCT00779389, NCT01218048, NCT02473731). Neoadjuvant regimens consisted of EGFR inhibitors (n = 83) or anti-ErbB3 antibody therapy (n = 9) within 28 days of surgery. Clinical to pathologic stage migration was compared with disease-free survival (DFS) and overall survival (OS) while adjusting for confounding factors using multivariable Cox regression. Circulating tumor markers validated in other solid tumor models were analyzed.

results92 of 118 patients were analyzed; all patients underwent surgery following neoadjuvant therapy. Clinical to pathologic downstaging was more frequent in patients undergoing neoadjuvant targeted therapy compared with control cohort (P = 0.048). Patients with pathologic downstage migration had the highest OS [89.5%; 95% confidence interval (CI), 75.7-100] compared with those with no stage change (58%; 95% CI, 46.2-69.8) or upstage (40%; 95% CI, 9.6-70.4; P = 0.003). Downstage migration remained a positive prognostic factor for OS (HR, 0.22; 95% CI, 0.05-0.90) while adjusting for measured confounders. Downstage migration correlated with decreased circulating tumor markers, SOX17 and TAC1 (P = 0.0078).

conclusionsBrief neoadjuvant therapy achieved pathologic downstaging in a subset of patients and was associated with significantly better DFS and OS as well as decreased circulating methylated SOX17 and TAC1.

Indexed as

Head and Neck NeoplasmsNeoadjuvant TherapyBiomarkers, TumorDisease-Free SurvivalHumansSquamous Cell Carcinoma of Head and NeckBiomarkers, Tumor

Identifiers

PMID36595540
PMCPMC11232033
OpenAlexW4313453618

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.